Assessing the accuracy of intracameral phenylephrine preparation in cataract surgery by Guthrie, Stuart et al.
 
 
 
 
 
Guthrie, S., Jensen, T., Hartley, R. C. , Ramaesh, K. and Lockington, 
D. (2018) Assessing the accuracy of intracameral phenylephrine preparation 
in cataract surgery. Eye, 32, pp. 1615-1620.  
(doi:10.1038/s41433-018-0143-y) 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
http://eprints.gla.ac.uk/161731/ 
                    
 
 
 
 
 
 
Deposited on: 04 May 2018 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk  
 
  
1 
 
Assessing the accuracy of intracameral phenylephrine preparation in cataract surgery 
  
S Guthrie1, T Jensen2, R C Hartley2, K Ramaesh1, D Lockington1  
1
Tennent Institute of Ophthalmology, Gartnavel General Hospital, 1053 Great Western Road, Glasgow, G12 0YN, 
United Kingdom. 
2
WestCHEM School of Chemistry, University of Glasgow, Glasgow G12 8QQ, United Kingdom. 
 
Corresponding author: David Lockington; davidlockington@hotmail.com 
Tennent Institute of Ophthalmology, Gartnavel General Hospital, 1053 Great Western Road, Glasgow, G12 0YN, 
United Kingdom. 
 
Phone: (+44) 141 211 1643 
Fax: (+44) 141 211 2054 
 
Word Count: 2198 
 
Keywords: intracameral phenylephrine, cataract surgery, accuracy, 1ml syringes, small volume, 
pupil dilation, floppy iris syndrome 
 
Conflict of interest: DL and KR have received speaker honoraria for educational meetings from 
Thea Pharmaceuticals, however, that company had no involvement in this project. 
 
Permission for publication: granted 
 
Acknowledgements: We would like to thank Dr David Young (University of Strathclyde) 
for his assistance with the statistics. TJ has received studentship funding from the 
Engineering and Physical Sciences Research Council. 
 
 
 
  
2 
 
Abstract 
Purpose: 
Unpreserved phenylephrine is often used as an off-licence intracameral surgical adjunct during 
cataract surgery to assist with pupil dilation and/or stabilise the iris in floppy iris syndrome. It 
can be delivered as a neat 0.2ml bolus of either 2.5% or 10% strength, or in a range of ad-hoc 
dilutions. We wished to assess the accuracy of intracameral phenylephrine preparation in clinical 
practice.  
Methods: 
Phenylephrine 0.2ml was analysed both neat (2.5% and 10%) and in diluted form (ratio of 1:1 
and 1:3). Samples were analysed using the validated spectrophotometric method.  
Results: 
A total of 36 samples were analysed. The standard curve showed linearity for phenylephrine (R2 
= 0.99). Wide variability was observed across all dilution groups. There was evidence of 
significant differences in the percentage deviations from intended results between dilutions 
(p<0.001). Mean percentage deviation for 1:3 dilution was significantly greater than neat 
(p=0.003) and 1:1 dilution (p=0.001). There was no evidence of a significant difference between 
1:1 and neat (p=0.827).  
Conclusions: 
Current ad-hoc dilution methods used to prepare intracameral phenylephrine are inaccurate and 
highly variable. Small volume 1ml syringes should not be used for mixing or dilution of drug. 
Commercial intracameral phenylephrine products would address dosage concerns and could 
improve surgical outcomes in cases of poor pupil dilation and/or floppy iris syndrome. 
Abstract Word Count: 213 
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Introduction  
The intracameral route is increasingly being utilised for drug delivery during cataract surgery.1-4 
Such medical adjuncts to surgery have been shown to reduce surgical complications and improve 
patient comfort.5-7 Intracameral phenylephrine has been shown in numerous studies to be safe 
and effective with respect to intra-operative pupil dilatation and also in the management of 
floppy iris syndrome.1-10 Some studies even suggest that intracameral phenylephrine is preferable 
to mechanical dilation devices during phacoemulsification, in terms of ease of use, reduced 
surgical time and lower financial costs.11 
Intracameral phenylephrine has a predictable positive action on pupil dilation, with a moderate 
mydriatic effect demonstrated in concentrations ranging from 0.15 mg/ml to 5.0 mg/ml 
(approximately 4.3mm diameter), and a non-linear significant increase in pupil size at higher 
concentrations (mean pupil size 5.80 mm ± 0.79 (SD) for 15.0 mg/mL (1.5%) and 6.65 mm ± 
0.57 for 30.0 mg/mL (3.0%)).12 This phenomenon is due to the fact that phenylephrine may bind 
and stimulate receptors other than the α(1)-receptor at the higher concentrations.  
However, it has been our clinical observation that the degree of pupil dilatation varies 
considerably between patients and can be less predictable than the literature suggests. It is 
common surgical practice in the United Kingdom that phenylephrine is delivered as a neat 0.2ml 
intracameral bolus of either 2.5% or 10% strength (derived from preservative-free Minims 
(Bausch & Lomb)) via a 1ml syringe, or following a range of ad-hoc dilutions, designed to 
reduce the exposure to associated excipients. These excipients include sodium metabisulphite, 
disodium edetate and purified water. 
Previous studies have highlighted the potential for a high degree in variation of drug 
concentration when using small volume 1 ml syringes for drug formulation, and have cautioned 
against this practice.13-19 Similar concerns have been previously raised with respect to the 
preparation of intracameral and intravitreal antibiotics.13,20,21 
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As previously mentioned, there are a range of surgeon preferences for diluting phenylephrine for 
intracameral use, but these ad-hoc methods are without a clear evidence base. Additionally, such 
protocols have not been assessed to evaluate dosage accuracy in the clinical environment. One 
possible reason for the unpredictable response to intracameral phenylephrine could be that the 
surgeon is unintentionally administering an inaccurately low dosage.  We therefore wished to 
assess the dosage accuracy of intracameral phenylephrine preparation in clinical practice. 
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Methods 
To replicate the clinical scenario of phenylephrine use in the theatre environment, 1ml syringes 
(Becton Dickinson, Plastipak), 18G x 1 1/2in blunt fill needles (Becton Dickinson) and 27G x 
⅞in Rycroft cannulae (Beaver-Visitec International) were used to draw up and deliver the 
solutions for analysis. Minims Phenylephrine hydrochloride 2.5% (Bausch & Lomb; 0.5ml vials 
containing 12.5mg of drug) and Minims Phenylephrine hydrochloride 10% (Bausch & Lomb;  
0.5ml vials containing 50mg of drug) were used as the source of phenylephrine. Balanced salt 
solution (BSS; Alcon) was used for the dilution protocols.  Hydrochloric acid (HCl) 0.3% was 
additionally used for further necessary dilution, and to prevent precipitation of phenylephrine out 
of the solution which would result in inaccuracies in concentration measurement. 
To accurately determine the concentration of the samples used in clinical practice, analysis was 
carried out using the spectrophotometric method.22 This validated technique measures how much 
a chemical absorbs light by measuring the intensity of light as the beam passes through the 
sample solution. The degree of absorption measured can then be directly correlated to the 
concentration of the drug, in the form of a standard curve. The relationship between absorbance 
and concentration must be linear if the standard curve is to be used to determine the 
concentration of the unknown samples. 
Phenylephrine absorption spectra range from 230 to 300nm with a peak absorption of 273nm.22 
Samples were therefore analysed using a spectrometer (model: Lambda 25 UV/VIS 
spectrometer, PerkinElmer) at an absorbance wavelength of 273 nm. It was determined after a 
series of dilutions of phenylephrine that linearity in the standard curve was achieved with a 
dilution factor of 77 times. This factor of dilution was therefore applied to all the samples 
analysed and each sample was repeated 6 times. The sample’s absorbance was then correlated 
against the standard curve to give the concentration of a 0.2ml solution. 
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The dilutions and analysis were carried out by an ophthalmology Specialty Registrar (SG) and a 
chemistry PhD student (TJ), in controlled conditions in the School of Chemistry, University of 
Glasgow, UK. 
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Results 
The control standard curve for phenylephrine showed linearity with an R2=0.99. As a result of 
this, the expected clinical concentration for 2.5% minims phenylephrine as a neat bolus would be 
25mg/ml, 12.5mg/ml for the 1:1 dilution, and 6.25mg/ml for the 1:3 dilution. The expected 
concentration for 10% minims phenylephrine as a neat bolus would be 100mg/ml, 50mg/ml for 
the 1:1 dilution, and 25mg/ml for the 1:3 dilution. 
A total of 6 samples for each of the 3 clinical dilution scenarios were analysed, for both the 2.5% 
and 10% phenylephrine minims, giving an overall total of 36 results. [See Table 1 for mean 
descriptive results, standard deviations, standard error of the mean and 95% confidence intervals]  
To summarise the results using the 2.5% minims phenylephrine: for the neat undiluted bolus, the 
mean result was 17.9mg/ml (range 9.5 –30, Standard Deviation (SD) 8.51). For the 1:1 dilution, 
the mean result was 11.67mg/ml (range 7.5–14, SD 2.37). For the 1:3 dilution, the mean result 
was 2.21mg/ml (range 0-4.7, SD 1.99). 
To summarise the results using the 10% minims phenylephrine: for the neat undiluted bolus, the 
mean result was 65.15mg/ml (range 37-85.2, SD 21.74). For the 1:1 dilution, the mean result was 
61.52mg/ml (range 32.1-84.3, SD 20.77). For the 1:3 dilution, the mean result was 37.4mg/ml 
(range 0-73.1, SD 31.1).  
There was wide variability observed in all the different dilution groups when the actual results 
were compared with the expected results. This was particularly seen with the 1:3 dilutions for 
both 2.5% and 10%, as the 95% confidence intervals didn’t contain the target values.  [See Table 
2 and boxplot in Figure 1] 
There was evidence of significant differences in the percentage deviations from intended results 
between the different dilutions (ANOVA; p<0.001). However, there was no evidence of a 
significant difference between the mean percentage deviations between the 2.5% and 10% 
concentrations for the different dilutions (p=0.108), suggesting that the intrinsic protocol was 
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being assessed in our study, rather than the original phenylephrine source. This allowed us to 
combine the results for both 2.5% and 10% into 3 groups, and perform statistical analysis (Tukey 
pairwise comparisons). Mean percentage deviation for the 1:3 dilution was significantly greater 
than for the neat group (p=0.003), and also when compared to the 1:1 dilution groups (p=0.001). 
There was no evidence of a significant difference between 1:1 dilution group and neat group 
(p=0.827).  
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Discussion 
We have demonstrated that there is a huge range of variability in the actual results and the 
difference from intended (expected) results when attempting to dilute intracameral 
phenylephrine, as demonstrated by the large 95% confidence intervals. Indeed, the 1:3 dilution 
group did not even contain the target value in their 95% confidence intervals. Our study has 
shown that the ad-hoc dilution methods currently used to prepare intracameral phenylephrine 
from Minims are inaccurate and can result in significantly lower concentrations of drug being 
administered. The potential consequences of such lower inadequate dosages are poor pupillary 
dilatation and continuation of floppy iris syndrome which could contribute to poorer cataract 
surgery outcomes. Additionally, it is important for the surgeon to accurately deliver a known 
concentration of any intracameral drug to reduce the potential risk of toxicity to the corneal 
endothelium associated with higher doses. A surgeon may be tempted to inject more intracameral 
phenylephrine on observing an ineffective response, and could inadvertently deliver unknown 
doses which could have an accumulative toxic effect. Particular care must be taken with 
phenylephrine in this regard, as it has been shown to have the highest concentration of free 
radicals of any of the commonly administered intracameral drugs, and accumulative free radical 
concentrations may contribute towards subsequent Toxic Anterior Segment Syndrome 
(TASS).23,24 
Our study shows that mathematical accuracy of these low volume dilution protocols do not 
correspond with accuracy in the clinical environment. This is predominantly due to the use of 
small volume (1ml) syringes, which are known to be inaccurate for the preparation of 
medications and should not be used for mixing of solutions.13-19 There are 3 factors related to 
small volume syringes which may have contributed towards our observed findings in our study, 
those being dead space, air bubbles and concentration gradients.  
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Firstly, ‘dead space’ within the syringe refers to the volume of a solution retained in the hub and 
needle when the plunger of the syringe is fully depressed. One study estimated this volume at 
0.07ml in a conventional 1ml syringe.19 This volume represents 35% of the total 0.2ml expected 
intracameral dosage, and has the consequence that only 0.13ml of potential drug volume would 
be administered when using an undiluted neat “bolus”. For the diluted protocols, this dead space 
volume represents undiluted BSS, which would subsequently be injected along with some 
(unknown) diluted drug solution. Both scenarios would result in a reduced intracameral drug 
concentration. Secondly, large air bubbles easily form within 1ml syringes, especially when 
drawing up small volumes of fluid from vials which have air pockets within them. This again has 
consequences of inaccurate dosing. Lastly, inadequate dilution within the syringe, due to the 
small chamber size preventing mixing, can result in a concentration gradient forming with the 
weakest dilution most anterior in the syringe. This weak 0.2ml would then subsequently be 
injected into the anterior chamber.  [See illustration in Figure 2] 
We have observed a wide range of unexpectedly variable concentrations of drug across all the 
dilution protocols. Rather than diluting the excipients and optimising the drug, this means the 
surgeon is actually delivering a random quantity of drug when following such protocols.  
We were interested to note the wide variability and inaccuracy associated with the use of a 1:3 
dilution technique. As previously mentioned, minims phenylephrine contains sodium 
metabisulphite and disodium edetate as excipients. In real life, these results suggest that the 
surgeon who has chosen a 10% source to maximise exposure to phenylephrine, yet wishes to 
minimise the exposure to excipients through 1:3 dilution in a small volume syringe, could 
inadvertently be either delivering the equivalent of a full concentration neat 10% bolus, or 
alternatively, an extremely diluted solution with neither significant levels of drug or excipients. 
This range of inaccuracy and variability is obviously unacceptable, but could it be harmful?  
Animal studies have investigated exposure to nonpreserved bisulfite-free phenylephrine 1.5% 
and demonstrated efficacy and safety.25 Another study evaluating endothelial cell morphology 
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and viability in the rabbit cornea did not detect any deleterious effect following intracameral 
exposure to bisulfite-containing phenylephrine (up to 1%).26 This would account for the relative 
safety of the current operating room practice of diluting preservative-free minims of 
phenylephrine for intracameral use.27 
There are justified concerns regarding the safety of using off-licence intracameral preparations 
and the potential for errors.13,28 These include local ocular risks such as endothelial damage from 
excipients or preservatives, and incorrect dosages from compounding pharmacies resulting in 
cases of Toxic Anterior Segment Syndrome (TASS).13,28 Rare cardiovascular effects such as 
hypertension have been reported, though the direct causation of such systemic events have been 
questioned.29-32 There has been a recently published case series of TASS following cataract 
surgery due to inadvertent administration of intracameral lidocaine and 2.5% phenylephrine 
preserved with 10% benzalkonium chloride, where 2 patients ultimately required corneal 
transplantation.33  
Our study has demonstrated the need for commercially available unpreserved intracameral 
phenylephrine to be available to ensure accuracy of dosage. There are currently 2 commercially 
available combination products which contain phenylephrine and are licenced for use in cataract 
surgery – Mydrane (Laboratoires THEA, Clermont-Ferrand, France), and Omidria (Omeros, 
Seattle). One bolus intracameral dose of 0.2 ml Mydrane solution contains 0.04 mg of 
tropicamide, 0.62 mg of phenylephrine hydrochloride, and 2 mg of lidocaine hydrochloride. 
Omidria contains phenylephrine 1.0% and ketorolac 0.3%; 4mls of which is diluted in 500 mL of 
the ophthalmic irrigating solution.34 Both these products have been shown to be safe and 
effective in cataract surgery, to dilate and maintain pupil size by preventing intraoperative 
miosis, and reducing postoperative ocular pain.1,2,5-7 These products do not require any additional 
preparation prior to use, and so eliminate any potential for dosage errors. In light of our study 
results demonstrating dosage variability with ad-hoc dilution of phenylephrine for intracameral 
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use, it would be prudent to use a pre-prepared, purpose-designed, commercial surgical adjunct, 
for both safety and efficacy.  
 
Conclusion: 
Our study is the first to evaluate intracameral phenylephrine preparation protocols for dosage 
accuracy. We have used a validated technique to measure the concentrations of the drug under 
laboratory conditions. Small volume (1ml) syringes are known to be inaccurate for the 
preparation of medications and should not be used for mixing of solutions. Our findings provide 
support to the clinical observation that the degree of drug effect can vary considerably between 
patients, due to the potentially low and variable concentration of phenylephrine delivered 
intracamerally. Having bespoke commercial intracameral phenylephrine products available 
would address this problem and could improve cataract surgical outcomes in the setting of poor 
pupil dilation and/or floppy iris syndrome.    
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What was known: 
 Intracameral adjuncts such as phenylephrine are increasingly used to improve pupil 
dilatation and address floppy iris syndrome in cataract surgery.  
 These off-licence agents are often delivered following ad-hoc dilutions to minimise 
endothelial toxicity, but the accuracy of this practice has not been investigated. 
 
What this paper adds: 
 Current ad-hoc dilution methods used to prepare intracameral phenylephrine are 
inaccurate and highly variable.  
 Small volume 1ml syringes should not be used for mixing or dilution of drug.  
 Using commercial intracameral phenylephrine products would address this problem and 
improve surgical outcomes in cases of poor pupil dilation and/or floppy iris syndrome. 
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Legend: 
 
Table 1: Table showing mean descriptive results, the standard deviations (StDev), Standard Error 
of the Mean (SE Mean) and 95% Confidence Intervals (CI) across a variety of dilutions. The 
intended result is in brackets for each dilution.  
Variable Intended 
result (mg/ml) 
Number of 
samples 
Mean StDev SE Mean 95% CI 
10% neat (100) 6 65.15 21.74 8.88 (42.33, 87.97) 
10% 1:1 (50) 6 61.52 20.77 8.48 (39.72, 83.32) 
10% 1:3 (25) 6 37.4 31.1 12.7 (4.7, 70.0) 
2.5% neat (25) 6 17.90 8.51 3.48 (8.97, 26.83) 
2.5% 1:1 (12.5) 6 11.667 2.374 0.969 (9.176, 14.158) 
2.5% 1:3 (6.25) 6 2.217 1.992 0.813 (0.126, 4.308) 
 
 
Table 2: Table showing mean percentage deviation from intended results. 
 
Descriptive Results for neat bolus (no dilution)  
 
Variable     Conc  N   Mean  StDev  Minimum     Q1  Median     Q3  Maximum 
% deviation  10%   6  33.20  23.37    10.70  13.78   24.30  62.33    63.00 
             2.5%  6   35.1   25.5      6.0    9.6    36.6   59.3     62.0 
 
Descriptive Results for 1:1 ratio dilution  
 
Variable     Conc  N   Mean  StDev  Minimum    Q1  Median     Q3  Maximum 
% deviation  10%   6   37.2   26.4      5.0   6.3    43.7   58.9     68.6 
             2.5%  6  13.87  13.54     0.00  7.20   10.80  19.00    40.00 
  
Descriptive Results for 1:3 ratio dilution   
 
Variable     Conc  N   Mean  StDev  Minimum    Q1  Median     Q3  Maximum 
% deviation  10%   6  105.8   68.8     18.8  44.0    95.6  183.1    192.4 
             2.5%  6   68.4   29.1     26.4  43.2    67.6  100.0    100.0 
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Figure 1: Box plot demonstrating percentage deviation from expected results, showing variability 
across all 6 clinical scenarios, and greater variability associated with the 1:3 dilution protocols. 
 
 
 
Figure 2: Colour photograph showing the lack of mixing and dead space in a 1ml syringe, 
illustrated by drawing up a minim of Fluorescein and 0.5ml of water for injection. 
 
